Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30440527 | 1.00 | HPGD (0.46) | HPGDNPC1TP53RAB9ATSHR | |
| SCHEMBL24267830 | 0.84 | ALKBH2 (0.46) | HPGDNPC1TP53RAB9AIRAK4 | |
| SCHEMBL29387563 | 0.84 | ALKBH2 (0.46) | HPGDNPC1TP53RAB9AIRAK4 | |
| SCHEMBL30092718 | 0.83 | MAPT (0.48) | HPGDNPC1TP53RAB9AGAA | |
| SCHEMBL18366925 | 0.83 | MAPT (0.48) | HPGDNPC1TP53RAB9AGAA | |
| SCHEMBL18367156 | 0.78 | CYP11B1 (0.39) | NPC1RAB9AIRAK4MAPK14MAPT | |
| SCHEMBL30587515 | 0.78 | CYP11B1 (0.39) | NPC1RAB9AIRAK4MAPK14MAPT | |
| SCHEMBL30204271 | 0.74 | ALOX15 (0.50) | HPGDNPC1TP53RAB9ATSHR | |
| SCHEMBL31403608 | 0.74 | TP53 (0.41) | TP53ALDH1A1CYP2C19KDM4ECYP1A2 | |
| SCHEMBL9601990 | 0.74 | NPC1 (0.55) | HPGDNPC1TP53RAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630554-B2 | Pyrimidinone compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2026-05-19 | — | — | US | disclosed |
| US-20240002388-A1 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-01-04 | — | — | US | disclosed |
| EP-4200281-A1 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | Hutchison Medipharma Limited (CN) | 2023-06-28 | — | — | EP | disclosed |
| CN-116249696-A | Pyrimidinone compounds and use thereof | 和记黄埔医药（上海）有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2022037585-A1 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022037585-A1 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-02-24 | — | — | WO | disclosed |
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | HPGD 2167/4885NPC1 541/4885TP53 4750/4885 |
| US-20240002388-A1 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | TYMP, DPYD, DHFR | HPGD 109/4885NPC1 2263/4885TP53 3943/4885 |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | LSS, LPXN, CYP1B1 | HPGD 2167/4885NPC1 541/4885TP53 4750/4885 |
| US-12630554-B2 | Pyrimidinone compounds and uses thereof | CYP2D6, TPMT, CYP2B6 | HPGD 924/4885NPC1 246/4885TP53 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.